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Abstract: The present work concerns the rational design and development of new inhibitors of 
acetylcholinesterase (AChE) based on the privileged xanthone scaffold.  In order to understand 
and rationalize the mode of action of these target structures a theoretical study was initially 
conducted.  From the results of rational design, a new variety of amphiphilic xanthone 
derivatives were synthesized, structurally characterized and evaluated as potential anti-Alzheimer 
agents. The results showed that most of the synthesized compounds exhibited high AChE 
inhibitory activity at the micromolar range (IC
50
, 0.46–12.09 μM). The synthetic xanthone 11 
showed the best inhibitory effect on AChE and a molecular modeling study revealed that 11 
targeted both the catalytic active site (CAS) and the peripheral anionic site (PAS) of AChE. 
Therefore, this compound could be considered as a potential lead compound towards new drugs 
for the treatment of Alzheimer’s disease. 
Keywords: Rational design; Synthesis; Amphiphilic xanthones; Acetylcholinesterase inhibitors; 
Molecular simulation. 
 
1. Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder that results in the progressive and 
irreversible cognitive impairment, memory loss, and decline in language.
1
 Several factors, both 
genetic and environmental, have been considered to play a crucial role in its pathogenesis: 
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progressive loss of cholinergic neural transmission, formation of a beta-amyloid plaques (Aβ-
plaques) that produces senile plaques (SPs) and neurofibrillary tangles (NFTs) of 
hyperphosphorylated tau protein.
2,3
  
The current standard of care for mild to moderate AD, based on the so-called cholinergic 
hypothesis, includes treatment with AChE inhibitors (AChEI) to improve cognitive function.
4,5
 
Some examples of drugs approved and licensed are rivastigmin, donepezil, and galanthamine. 
Although these drugs are part of the same therapeutic class (AChEI), they differ in their 
pharmacology and pharmacokinetics and possess some side effects. Unfortunately, all the 
approved drugs for AD offer symptomatic treatment, but are unable to prevent disease 
progression or alter the outcome of the disease. Therefore, it is compulsory to discover new anti-
Alzheimer drug candidates. To this purpose, computational approaches can be valuable in the 
design of new compounds with improved pharmacological profile. Molecular dynamics, 
molecular docking and some other in silico studies have been reported targeting AChE.
6–8
 Ligand 
docking is designed to find the best mode of interaction between a small ligand and a large 
macromolecular receptor and represents one of the most widely used tools in ligand and drug 
design/screening. Molecular dynamics simulation, on the other hand, is a successful and well-
established method in the computational study of structure and dynamics of biological 
macromolecules. 
From the chemical point of view, xanthones represent a class of oxygenated heterocyclic 
compounds with a dibenzo--pyrone scaffold. Its privileged structure is broadly distributed in 
Nature and display a wide range of biological activities, such as antibacterial, anti-inflammatory, 
antitumoral and α-glucosidase inhibitory activities.
9-12
 Xanthones can be considered as 
biocompatible structures since their derivatives are capable of interacting with several different 
targets.
13
 Currently, these class of compounds (natural and synthetic) that act on molecular targets 
of neurodegenerative diseases are grounds for study and exploration.
14,15
 Particularly, xanthones 
derivatives as anti-cholinesterase agents have received significant attention in the last years 
(Figure 1).
16-19
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Figure 1. Figure 1. a) Some representative structures of xanthone derivatives with AChE 
inhibitory activity. b) 1,3-dihydroxyxanthone Mannich base derivatives with anti-AChE activity. 
In a recent work, a series of novel 1,3-dihydroxyxanthone Mannich bases derivatives have 
been identified as anti-AChE agents (Figure 1b).
20
 Within this context, we decided to carry out 
molecular docking simulations and molecular dynamics simulations with the aim of establishing 
the molecular basis for the interaction between these compounds and AChE, in order to 
understand and rationalize the previous experimental results. In addition, we perform rational 
modifications on this kind of compounds in order to improve their inhibitory effect. Finally, a 
new series of 1,3-dihydroxyxanthone derivatives was synthesized and their inhibitory effects on 
AChE were evaluated. 
 
 
 
 
 
2. Results and Discussion 
2.1 Rational design 
In this section, we present the results of the computational studies we performed in order to 
rationalize the binding mode of the already proposed xanthonic ligands and to reengineer them 
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with the aim of obtaining ligands with improved affinity (we refer the reader to the Experimental 
section for the description of the techniques employed). 
We employed docking studies to rationalize the interaction mode of a series of 1,3-
dihydroxylated xanthone derivatives (Figure 1b). Such studies indicated that these molecules 
generally interacted with residues from the bottleneck region such as Phe 330, residues from 
peripheral anionic site (PAS) as Tyr 334 and Asp 72, while the interaction with Trp 84 from the 
catalytic active site (CAS) was always present (Figure 2). 
 
Figure 2. 2D depiction of 1a docked into the binding site of AChE highlighting the protein 
residues that form the main interactions with the different structural units of the inhibitor. 
Hydrogen-bonding interactions are represented with green broken lines. 
 
In order to determine the residues that most contribute to the ligand-enzyme interaction we 
performed free energy calculations by means of the MM/GBSA method (as implemented in the 
mm_pbsa program of the AMBER 12 package). This analysis enabled us to identify the π-stacking 
interaction of Trp 84 as the most relevant in all complexes studied. Additionally, we detected a 
possible salt bridge interaction involving Glu 199, which appeared intermittently in time for some 
of the Mannich derivatives (for example in compound 2a). Nonetheless, this interaction was 
established in detriment of other ones, as for example that of Trp 432 in the case of 2a. 
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In Figure 3.a, we display the way in which the distance between the N atom of 2a and the O 
atom of the lateral chain of Glu 199 varies with time.  In Figures 3.b and 3.c, we show the free-
energy per residue decomposition for the complex AChE-2a. Figure 3.b corresponds to the 
period of time that goes from 0 to 4 ns, when the interaction with Glu 199 is established (in 
detriment of other interactions). In turn, Figure 3.c corresponds to the time window that spans 
from 5 to 10 ns, where the energetically most significant interaction is the one formed by Trp 84.  
 
Figure 3. a) Distance between the N atom of 2a and the O atom of the lateral chain of Glu 199. 
b) and c) Free-energy per residue decomposition for the complex AChE-2a. The period of time 
that goes from 0 to 4 ns is shown in b); while period of time between 5 to 10 ns is shown in c). 
We also provide a correlation of the free-energy values and the activity values reported for 8 
compounds of this series. The data yielded a correlation with a R
2
 value of 0.65 (Table S1: see 
supplementary material). 
a) 
b) 
c) 
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Finally, a GIST study (Analysis of water thermodynamics using Grid Inhomogeneous Solvation) 
21
 allowed us to obtain the hydration map for the binding site of these compounds in AChE. This 
approach determined the existence of regions with high energy waters, that is, “easily removable” 
water. Such regions were determined as that with a water density more than 1.9 times larger than 
that of the bulk and with free energy values lower than DeltaG – 0.5 (Kcal/mol).22 Then, we 
superimposed the configurations adopted by the different ligands in their complexes with AChE 
and the water map already generated. Thus, we quantified the number of water “boxes” that each 
ligand displaces upon binding and we employed this value as a second score function. 
The protein hydration map was performed for three different time periods:  
1) From 0 to 20 ns, with a spacing between consecutive configurations of 1 ps. 
2) From 0 to 100 ns, with a spacing between consecutive configurations of 5 ps. 
3) From 100 to 120 ns, with a spacing between consecutive configurations of 1 ps.  
On the other hand, we defined two kinds of configurations for each ligand: 
A) Binding mode obtained from the molecular docking simulations. 
B) Starting from the docking results we performed molecular dynamics simulations and then 
we selected configurations for each ligand after constant root mean squared displacement (RMSD) 
values were reached. 
We obtained good correlations for the three-time periods under study when the configurations 
of the different compounds were obtained by means of molecular dynamics simulations (B). The 
correlation values obtained were R
2
 = 0.78 for the first-time span considered and R
2
 = 0.75 for the 
second and third time periods. In the case of the configurations obtained directly from molecular 
docking simulations, the correlation values were: R
2
 = 0.7, 0.63 and 0.58 for the three respective 
time periods studied (Table S1: see supplementary material).). 
Finally, on the basis of the hydration map of the GIST study, we qualitatively evaluated the 
ability of the different compounds to appropriately mimic the role of the water molecules they 
displace upon complex formation. For example, we evaluated their ability to locate hydrophilic 
atoms or groups in regions where water is “strongly bonded”. To this end, we generated a map for 
  
 
7 
water molecules whose energy was less than -0.5 (Kcal/mol) and we superimposed this map with 
the configurations obtained from the MD of each ligand. In all cases, we could realize that the 
hydroxyl group in position 1 is located in a region where water interacts favourably with the 
protein. The same happens with the oxygen atom of the carbonyl and the oxygen from the 
ether/hydroxyl in position 3 of the xanthonic backbone (Figure 4). 
 
Figure 4. Complex between 2a and AChE. Cyan: 2a and AChE residues side chains. Dark 
gray spheres: regions where water is “strongly bonded”.    
 
In summary, by means of free energy calculations we were able to identify two main interaction 
regions. In one hand, the fused tricyclic system interacting by means of π-stacking with Trp 84 
and Phe 330, and by hydrogen bond with Tyr 334. On the other hand, the positively charged 
region of the amine group with the ability to interact via a salt bridge with Glu 199. 
Additionally, the qualitative results from the GIST study (map of strongly bonded water) point 
to the fact of the relevance of preserving the hydroxyl (or other hydrophilic substituent) in position 
1 given its capability to appropriately replace the water molecules at such region while also being 
able to interact with residues of the protein (Tyr 334).   
Through Molecular Dynamics simulation studies was observed that Mannich bases studied 
oscillate between these two interaction regions, but they are unable to satisfy or interact with both 
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sites simultaneously. Thus, an appropriate reengineering of these compounds to achieve this goal 
is expected to improve their activity. 
 
2.2 Proposal of new xanthone derivatives 
In the light of the former results we proposed a new series of 1,3-dihydroxylated xanthone 
analogues, appropriately substituted in order to interact simultaneously with both regions. On the 
one side, this compound interacts by π-stacking via the fused tricyclic system with Trp 84 and Phe 
330, while establishing a hydrogen bond with Tyr 334 by means of the hydroxy group in position 
1. On the other hand, given the introduction of an appropriate linker, its positively charged amino 
group is now able to form a salt bridge with Glu 199. A series of additional interactions, mainly of 
hydrophobic nature should be included (interactions already present in the Mannich bases). Thus, 
theoretical studies for a series of derivatives with the proposed motif presented in Figure 6 were 
performed.  
Figure 5. Proposed motif for new 1,3-dihydroxyxanthone derivatives. 
 
The linker lengths studied varied between 3 and 6 methylenes, including ethyl groups as 
substituents in the charged group. In Figure 5, we include all new compounds theoretically (by 
means of Molecular Docking and Molecular Dynamics) and/or empirically evaluated. In 
supplementary material, we include Molecular Docking results (Score functions) for an expanded 
series of compounds, including some different amine groups for each linker length. 
Table 2. Amphiphilic xanthones 6-12 biologically tested. 
Compound 
Linke
r 
lenght 
Amino group 
IC50  SD 
(M) 
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6 3 diethylamine 3.29  0.26 
7 4 diethylamine 4.86  0.50 
8 5 diethylamine 0.69  0.10 
9 6 diethylamine 2.37  0.33 
10 5 pyrrolidine 0.95  0.19 
11 5 piperidine 0.46  0.02 
12 5 morpholine 12.09  1.87 
tacrine
a
 - - 0.029  0.003 
a Reference inhibitor. 
 
The results of the molecular docking revealed the ability of all the compounds to interact 
electrostatically (salt bridge) with Glu 199, while the interactions of the fused tricyclic system were 
similar to that of the former Mannich analogues. That is, this series of new analogues preserve the 
interactions present in the 1,3-dihydroxylated xanthonic Mannich derivatives but also add the 
electrostatic interaction. On the other hand, and given the structural similarity of the xanthonic 
skeleton with tacrine (reference inhibitor), we compared their modes of interaction with AChE. 
The position and interactions of the fused tricyclic system of different xanthones studied were 
similar to tacrine (Figure 6a), although it is important to mention that tacrine is able to form a 
hydrogen bond interaction with the His 440 (Figure 6b), while xanthones do not exhibit this 
interaction. 
In order to estimate the activity range for the new xanthone derivatives and to determine the 
optimal linker length, we performed free energy calculations (GBSA) and, in the same way as 
done for the xanthonic Mannich derivatives, we calculated the quantity of low energy water 
“boxes” displaced by each of the new proposed analogues (Table1). The latter study was 
conducted again over three different time periods and for ligand configurations obtained both 
directly for the molecular docking results (A) and for the respective molecular dynamics 
simulations (B). From the results of Table 1, we concluded that the better lengths for the linker 
would be 5 or 6 methylenes.  
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Table 1.  Results of new 1,3-dihydroxyxanthone derivatives theoretically evaluated. 
Compound 
Score 
docking 
GBSA 
(Kcal/mol) BOX-1A* BOX-1B* BOX-2A* BOX-2B* BOX-3A* BOX-3B* 
6 -11.41 -28.67 279 169 294 178 305 183 
7 -11.92 -36.6 418 280 435 293 431 296 
9 -12.55 -49.18 429 418 442 413 443 415 
8 -12.3 -48.7 416 334 430 350 426 381 
(*) Number of water “easily removable boxes”. 1A, 1B, 2A, 2B, 3A and 3B refers to time periods and kinds of configurations 
(Docking or Molecular Dynamics). 
 
 
Figure 6. A) Superposition of compound 11 (bonds) and tacrine (CPK) both in complex with 
AChE. B) 2D depiction of tacrine in complex with AChE (PDB: 1ACJ) highlighting the protein 
residues that form the main interactions with the different structural units of the inhibitor. 
Hydrogen-bonding interactions are represented with green broken lines. 
 
Also, we carried out a decomposition of the free energy change per residue in order to quantify 
the possible interactions for each ligand–AChE complex. Figure 7displays, superimposed, the free 
energy decompositions for the different complexes. From the free energy values of the interaction 
with Glu 199, we could infer that the optimal linker length would be that of five methylenes. 
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Figure 7. Free energy values for the interaction between compounds 6-9 with Glu 199. 
 
In order to contrast with the theoretical results, we performed the synthesis of this new series of 
compounds 6-9 and their activities as AChE inhibitors were experimentally determined by 
Ellman’s method (Table 2).23 Finally, taking into account that compound 8, with a five methylenes 
linker, gave the best experimental results (lowest IC50), and based on the results of molecular 
docking (see supplementary material), we expanded the series by changing the charged amino 
group to obtain compounds 10-12. 
 
 
2.3 Chemistry 
The synthesis of hydroxylated xanthone 1 was achieved according to the general reaction 
pathway outlined in Scheme 1. The building block 1 was obtained by one-pot synthesis using 
Eaton’s reaction. In Eaton’s protocol, 1 was obtained by the condensation of 2-hydroxybenzoic 
acid with phloroglucinol in the presence of a mixture of phosphorus pentoxide-methanesulfonic 
acid (Eaton’s reagent) as condensing agent (Scheme 1).24 The precursor xanthone 1 was obtained 
as a yellow solid (yield 70%) after purified by column chromatography using silica gel 60. 
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Scheme 1. Synthesis of 1-hydroxyl-3-aminoalkoxy xanthone derivatives 6-12. Reagents and 
conditions: (i) P2O5, methanesulfonic acid, 80 °C, 2 h; (ii) Br(CH2)nBr, K2CO3, dry acetone, r.t, 
24 h; (iii) secondary amine, dry acetone, r.t,  24 h. 
 
The subsequent etherification of the hydroxyl group in the position 3 of 1,3-dihydroxyxanthone 
(1) with dibromoalkanes was carried out in K2CO3/dry acetone to offer the key intermediates 2-5, 
which possessed various side chains with different length. Then, compounds 2-5 were treated with 
appropriate secondary amines at room temperature in the presence of dry acetone to give the 
target compounds 6- 12 in very good yield (75-92%).
25
 The new compound 6, 8, 9, 11 and 12 
were fully characterized by IR and NMR. The NMR assignments are provided explicitly in the 
Experimental section. 
 
 
 
 
2.4 Biology  
From Table 2, we could see that the theoretical predictions on the chain length were correct 
since the best activity within the test series was achieved by compounds 8, 10 and 11. Among 
them, compound 11, with a piperidine moiety as the amino group, elicited the strongest AChE 
inhibition. These results indicate that the 1,3-dihydroxyxanthone derivatives proposed in this work 
do in fact improve the experimental affinity as compared to the previously proposed Mannich 
bases. Compound 12 turned out to be the weakest inhibitor of the series, even though the linker 
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was five methylenes long. This result can be explained by the presence of a second heteroatom in 
the amino group. The electron-withdrawing effect of the oxygen atom might reduce the electronic 
density of the tertiary amine, thereby affecting protonation, which could, in turn, diminish the 
interaction between the ammonium and Glu199. A similar effect was observed by Li et al. for 
flavonoids linked to cyclic amines possessing an additional nitrogen or oxygen atom in the terminal 
group.
26
 Also, we have observed the same effect in morpholine derivatives of cativic acid, a 
diterpenoid with moderate AChE inhibition.
27 
Table 2. Amphiphilic xanthones 6-12 biologically tested. 
Compound Linker 
lenght 
Amino group IC50  SD (M) 
6 3 diethylamine 3.29  0.26 
7 4 diethylamine 4.86  0.50 
8 5 diethylamine 0.69  0.10 
9 6 diethylamine 2.37  0.33 
10 5 pyrrolidine 0.95  0.19 
11 5 piperidine 0.46  0.02 
12 5 morpholine 12.09  1.87 
tacrine
a
 - - 0.029  0.003 
a Reference inhibitor. 
 
In turn, the expected activity range is consistent for the analogues with linkers with 5 and 6 
methylene length. The remaining analogues (linkers with 3 or 4 methylenes) while yielding 
affinities lower than the ones with 5 or 6 methylenes, presented better experimental inhibition 
values in comparison with the theoretical expectations. 
 
2.5 Perspectives for future work  
For the configuration adopted in the theoretical studies by the analogue with the overall best 
activity, compound 11, we superimposed the strongly bonded water map or low-energy water (the 
theoretical configuration was that adopted in the molecular dynamics once the RMSD values get 
constant).  In this way, we verified (Figure 8) that in general the positions with tightly bound 
water are well compensated by the ligand except that in the linker region. Thus, we could modify 
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the chemical nature of the linker (make it more hydrophilic) and thus possibly increase the 
inhibitory potency of this analogue. 
 
Figure 8. Complex between 11 and AChE. Cyan: 11 and AChE residues side chains. Dark gray 
spheres: regions where water is “strongly bonded”. 
 
3. Conclusions 
   In summary, the theoretical studies presented in this work nicely rationalize the binding 
mode to AChE of already proposed Mannich bases
20
 and enabled us to successfully reengineer 
them towards lead compounds of mildly improved affinity (roughly one order of magnitude 
enhancement), as accurately confirmed by the biological assays we also hereby provide. In this 
context, a new series of 1,3-dihydroxyxanthone derivatives were easily synthesized by 
modifications to known procedures
25
 and subsequently biologically evaluated against AChE. In 
particular, amphiphilic xanthone 11 showed the best inhibitory effect (IC
50
: 0.46 M), which 
could be considered as a useful prototype for further development of new anti-AD agents.. 
 
4. Experimental 
4.1. General 
All operations were performed under an argon atmosphere using standard Schlenk techniques. 
Solvents were dried and distilled in accordance with standard procedure.
28
 Reactions were 
monitored by thin-layer chromatography (TLC) on silica gel plates (60F-254) visualized under 
UV light and/or using 5% phosphomolybdic acid in ethanol. All 
1
H and 
13
C NMR spectra were 
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recorded at room temperature in CDCl
3
, DMSO-d
6
 or Acetone-d
6
 on a Bruker Avance ARX-300 
spectrophotometer. Chemical shifts (δ) are reported in parts per million (ppm) from 
tetramethylsilane (TMS) using the residual solvent resonance (CDCl
3
: 7.26 ppm for 
1
H NMR and 
77.16 ppm for 
13
C NMR; DMSO-d
6
: 2.50 ppm for 
1
H NMR and 39.50 ppm for 
13
C NMR; 
Acetone-d
6
: 2.09 ppm for 
1
H NMR, 30.60 and 205.87 ppm for 
13
C NMR). Multiplicities are 
abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet; brs = broad 
signal). IR spectra were recorded on a Perkin-Elmer Paragon 1000 FT-IR spectrometer in the 
ATR mode at room temp. Melting points were determined using a Büchi 510 apparatus and are 
not corrected. UV spectra were recorded on a JASCO V-630BIO spectrophotometer. Mass 
spectra (EI) were obtained at 70 eV on an Agilent CG-78903 instrument equipped with a MS-
5977A MSD selective mass detector. The purity of volatile compounds and the chromatographic 
analyses (GC) were determined with a GC Shimadzu (GC-14B) with a flame ionization detector 
equipped with a HP-5MS column (30 m × 0.25 mm × 0.25 μm) using nitrogen as carrier gas. 
High resolution mass spectra were recorded on Thermo Fisher LTQ Orbitrap XL, (for EI) and a 
Finnigen MAT 95 (for ESI). Flash column chromatography was performed using Macherey 
Nagel MN Kieselgel 60M (0.040- 0.063 mm / 230-240 mesh ASTM). Acetylcholinesterase from 
electric eel (type VI-S), 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB), acetylthiocholine iodide 
(ATCI) and tacrine were purchased from Sigma. 
 
4.2. Synthesis of 1,3-dihydroxyxanthone (1)
24
 
Under argon atmosphere, a mixture of phosphorus pentoxide (0.90 g, 6.35 mmol) and 
methanesulfonic acid (10.13 g, 15 mL, 0.10 mol) was heated on a steam bath (90 °C) until a clear 
solution was obtained (30 minutes). Then, a mixture of phloroglucinol (0.38 g, 3 mmol) and 2-
hydroxybenzoic acid (0.46 g, 3 mmol) was added to the reaction mixture. This mixture was 
stirred at reflux (80 ˚C) for 1 h and the progress of the reaction was monitored by TLC. After 
completion, the reaction mixture was poured into ice-water. The resulting orange solid was 
collected by filtration, washed with water, dried in air, and the residue was then purified by 
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column chromatography using silica gel 60. The desired product 1 (0.48 g, 2.1 mmol, 70%) was 
eluted with hexane/EtOAc (90:10) as a yellow solid. m.p.: 255-257 °C; 
1
H NMR (300 MHz, 
DMSO-d
6
): δ 6.20 (d, J = 2.1 Hz, 1 H), 6.37 (d, J =2.1 Hz, 1 H), 7.42-7.45 (m, 2 H), 7.55 (td, J = 
8.0 Hz, 1 H), 8.10 (dd, J = 8.0, 1 H, 1.5 Hz), 11.07 (s, 1 H), 12.80 (s, 1 H). 
13
C NMR (DMSO-d
6
, 
75 MHz): δ 95.1, 99.1, 103.1, 118.2, 120.7, 125.3, 126.6, 135.7, 156.4, 158.1, 163.8, 165.2, 
180.4. IR (KBr): ν 3327, 1654, 1610, 1570, 1491, 1470, 1445, 1222, 1163, 1078, 827, 762 cm
-1
. 
 
4.2.1 General procedure for the synthesis of 3-bromoalkoxy substituted xanthones (2-5) 
Under argon atmosphere, a mixture of 1 (100 mg, 0.4 mmol) and K
2
CO
3
 (110 mg, 0.8 mmol) in 
dry acetone (2 mL), 1,n-dibromoalkane (0.6 mmol, n > 2) was slowly added by syringe. The 
reaction mixture was stirred at room temperature for about 24 h, with monitoring by TLC. The 
reaction mixture was poured into ice-water. The resulting yellow solid was collected by filtration, 
washed with water, dried in air, and the residue was then purified by column chromatography 
using silica gel 60. The compounds 2-5 were eluted with hexane/EtOAc (95:5) as yellow solids. 
 
3-(3-Bromopropoxy)-1-hydroxy-9H-xanthen-9-one (2)
25
 
Isolated yield: 60% (pale yellow solid) from compound 1 and 1,3-dibromopropane. m.p.: 119-
121 °C; 
1
H NMR (300 MHz, CDCl
3
): δ 2.28-2.39 (m, 2H), 3.54 (t, 2H), 4.12 (t, 2H), 6.34 (d, 
1H), 6.43 (d, 1H), 7.42-7.44 (m, 2H), 7.71 (ddd, 1H), 8.24 (dd, 1H), 12.85 (s, 1H, OH). 
13
C 
NMR (75 MHz, CDCl
3
): δ 29.6, 30.0, 66.0, 93.2, 97.5, 104.1, 117.6, 120.1, 124.1, 125.9, 135.1, 
156.1, 157.7, 163.6, 165.8, 180.8. IR (KBr):  3450, 2965, 1660, 1611, 1575, 1465, 1297, 1160, 
1037, 828 cm
-1
. 
3-(4-Bromobutoxy)-1-hydroxy-9H-xanthen-9-one (3)
25
 
Isolated yield: 45% (yellow solid) from compound 1 and 1,4-dibromobutane. m.p.: 132-135 °C; 
1
H NMR (300 MHz, CDCl
3
): δ 2.76-2.79 (m, 4H), 3.63 (t, 2H), 4.25 (t, 2H), 6.38 (d, 1H), 6.59 
(d, 1H), 7.49 (m, 1H), 7.56 (d, 1H), 7.87 (ddd, 1H), 8.23 (dd, 1H), 12.88 (s, 1H, OH). 
13
C NMR 
(75 MHz, CDCl
3
): δ 27.7, 29.4, 33.3, 67.6, 93.2, 97.5, 104.0, 117.6, 120.6, 124.1, 125.9, 135.5, 
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156.1, 157.8, 163.6, 166.1, 180.8. IR (KBr): 3546, 2959, 1663, 1609, 1572, 1469, 1299, 1158, 
1081, 824 cm
-1
.  
3-(5-Bromopentyloxy)-1-hydroxy-9H-xanthen-9-one (4)
25
 
Isolated yield: 50% (yellow solid) from compound 1 and 1,5-dibromopentane. m.p.: 130-132 °C; 
1
H NMR (300 MHz, CDCl
3
): δ 1.31-1.40 (m, 2H), 1.85-2.00 (m,4H), 3.46 (t, 2H), 4.01 (t, 2H), 
6.33 (d,1H), 6.41 (d, 1H), 7.34-7.40 (m, 2H), 7.70 (ddd, 1H), 8.24 (dd, 1H), 12.85 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): δ 24.8, 28.3, 32.5, 33.5, 68.3, 93.3, 97.5, 104.1, 117.7, 124.1, 126.1, 
128.0, 135.1, 156.1, 157.8, 163.7, 166.3, 180.9. IR (KBr):  3460, 2946, 1661, 1609, 1573, 
1481, 1296, 1163, 1038, 820 cm
-1
. 
3-(6-Bromohexyloxy)-1-hydroxy-9H-xanthen-9-one (5)
25
 
Isolated yield: 45% (yellow solid) from compound 1 and 1,6-dibromohexane. m.p.: 139-141 °C; 
1
H NMR (300 MHz, CDCl
3
): δ 1.35-1.58 (m, 4H), 1.81-1.92 (m, 4H), 3.40 (t, 2H), 4.03 (t, 2H), 
6.31 (d, 1H), 6.39 (d, 1H), 7.36-7.41 (m, 2H), 7.66 (ddd, 1H), 8.24 (dd, 1H), 12.85 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): δ 25.3, 27.9, 28.9, 32.7, 33.8, 68.5, 93.3, 97.5, 103.9, 117.7, 120.7, 
124.1, 125.9, 135.0, 157.8, 163.7, 165.1, 166.3, 180.8. IR (KBr):  3430, 2945, 1662, 1602, 
1573, 1462, 1296, 1179, 1074, 823 cm
-1
. 
 
4.2.2. General procedure for the synthesis of 1-hydroxy -3-aminoalkoxy xanthone derivatives (6-
12) 
Under argon atmosphere, a mixture of 2-5 (1 mmol) in dry acetone (1 mL), corresponding 
secondary amine (diethylamine, pyrrolidine, piperidine or morpholine, 2.5 mmol) was added 
dropwise by a syringe. The resulting solution was stirred at room temperature until the 
completion of the reaction (24-48 h). The progress of the reaction was monitored by TLC. The 
reaction mixture was poured into ice-water. The resulting yellow solid was collected by filtration, 
washed with water, and then dried in vacuo to give compound 6-12 respectively without further 
purification. 
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 3-(3-(diethylamino)propoxy)-1-hydroxy-9H-xanthen-9-one (6) 
Isolated yield: 85% (yellow solid) from compound 2 and diethylamine. m.p.: 190-191 °C; 
1
H 
NMR (300 MHz, CDCl
3
): δ 1.06 (t, 6H), 1.82- 1.86  (m, 2H), 2.42- 2.48 (m, 4H), 2.55- 2.59 (m, 
2H),  4.05 (t, 2H), 6.34 (d, 1H), 6.41 (d, 1H), 7.45- 7.50 (m, 2H), 7.71 (ddd, 1H), 8.23 (dd, 1H), 
12.85 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): δ 8.8, 29.6, 47.1, 49.2, 65.5, 93.1, 97.5, 104.2, 
117.5, 120.3, 124.2, 125.9, 135.1, 156.1, 157.8, 163.5, 165.2, 180.9. IR (film):  3430, 3055, 
2986, 1653, 1606, 1468, 1265, 1169, 824, 743 cm
-1
. HRMS (EI) m/z: 341.1627 calcd for 
C
20
H
23
NO
4
, found 341.1631. 
3-(4-(Diethylamino)butoxy)-1-hydroxy-9H-xanthen-9-one (7)
25
 
Isolated yield: 80% (yellow solid) from compound 3 and diethylamine; m.p: 181-183°C; 
1
H 
NMR (300 MHz, CDCl
3
): δ 1.14 (t, 6H), 1.70-1.75 (m, 2H), 1.77- 1.84 (m, 2H), 2.91-3.02 (m, 
6H), 4.18 (t, 2H), 6.43 (d, 1H), 6.67 (d, 1H), 7.60- 7.65 (m, 1H), 7.73 (d, 1H), 7.90 (ddd, 1H), 
8.17 (dd, 1H), 12.81 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): δ 8.7, 20.6, 26.2, 46.8, 51.2, 67.5, 
93.0, 97.3, 103.9, 117.5, 120.5, 124.0, 125.7, 135.1, 155.9, 157.7, 165.6, 163.4, 180.7. IR (film): 
 3432, 3051, 2985, 1650, 1603, 1465, 1262, 1170, 823, 745 cm
-1
. HRMS (EI) m/z: 355.1784 
calcd for C
21
H
25
NO
4
, found 355.1789. 
3-((5-(diethylamino)pentyl)oxy)-1-hydroxy-9H-xanthen-9-one (8) 
 Isolated yield: 80% (yellow solid) from compound 4 and diethylamine. m.p.: 150-151°C, 
1
H 
NMR (300 MHz, CDCl
3
): δ 1.05 (t, 6H), 1.51-1.70 (m, 4H), 1.82-1.93 (m, 2H), 2.48-2.52 (m, 
6H), 4.05 (t, 2H), 6.34 (d, 1H), 6.41 (d, 1H), 7.45- 7.51 (m, 2H), 7.71 (ddd, 1H), 8.23 (dd, 1H), 
12.85 (s, 1H, OH),  
13
C NMR (75 MHz, CDCl
3
): δ 24.1, 26.8, 29.1, 47.1, 52.9, 68.7,  93.3, 97.6, 
104.2, 117.8, 124.1, 126.1, 135.0, 156.4, 157.8, 163.3, 166.5, 180.9, IR (film):  3440, 2964, 
2790, 1660, 1603, 1571, 1472, 1329, 1298, 1179, 1079, 821, 758 cm-1. HRMS (EI) m/z: 
369.1940 calcd for C
22
H
27
NO
4
, found 369.1944. 
 
 
3-((6-(diethylamino)hexyl)oxy)-1-hydroxy-9H-xanthen-9-one (9) 
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Isolated yield: 75% (yellow solid) from compound 5 and diethylamine. m.p.: 110-111 °C; 
1
H 
NMR (300 MHz, CDCl
3
): δ 1.06 (t, J = 8.0 Hz, 6H), 1.24 –1.34 (m, 2H), 1.42–1.55 (m, 4H), 
1.80 (tt, J = 7.9, 4.7 Hz, 2H), 2.42 (t, J = 7.6 Hz, 2H), 3.01 (q, J = 8.0 Hz, 4H), 4.11 (t, J = 4.7 
Hz, 2H), 6.37 (d, J = 1.9 Hz, 1H), 6.60 (d, J = 2.1 Hz, 1H), 7.26 – 7.35 (m, 2H), 7.56 (td, J = 
7.5, 2.0 Hz, 1H), 8.00 (dd, J = 7.5, 2.0 Hz, 1H), 12.71 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): 
δ 8.7, 23.4, 25.6, 26.7, 28.8, 29.8, 46.5, 51.3, 68.5, 93.2, 97.5, 103.9, 117.6, 120.7, 124.1, 125.9, 
135.1, 156.1, 157.8, 163.6, 166.3, 180.9. IR (film):  3445, 2955, 1665, 1605, 1571, 1468, 1320, 
1170, 824, 747 cm
-1
. HRMS (EI) m/z: 383.2097 calcd for C
23
H
29
NO
4
, found 383.2093. 
1-Hydroxy-3-(5-(pyrrolidin-1-yl)pentyloxy)-9H-xanthen-9-one (10)
25
 
Isolated yield: 92% (pale yellow solid) from compound 4 and pyrrolidine. m.p.: 105- 106°C; 
1
H 
NMR (300 MHz, CDCl
3
): δ 1.47-1.54 (m, 2H), 1.56-1.63 (m, 2H), 1.74-1.80 (m, 4H), 1.81-1.87 
(m, 2H), 2.44-2.52 (m, 6H), 4.03 (t, 2H), 6.31 (d, 1H), 6.39 (d, 1H), 7.33- 7.38 (m, 1H), 7.40 (d, 
1H), 7.69 (ddd, 1H), 8.22 (dd, 1H), 12.82 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): δ 23.5, 24.3, 
28.8, 29.0, 54.3, 56.5, 68.7, 93.3, 97.6, 103.9, 117.7, 120.4, 124.1, 126.0, 135.0, 156.2, 157.8, 
163.7, 166.4, 180.9. IR (film):  3430, 2949, 2793, 1662, 1608, 1571,1468,1316,1299,1166, 
1082, 824, 763 cm
-1
. HRMS (EI) m/z: 367.1784 calcd for C
22
H
25
NO
4
, found 367.1789. 
1-hydroxy-3-((5-(piperidin-1-yl)pentyl)oxy)-9H-xanthen-9-one (11) 
Isolated yield: 80% (yellow solid) from compound 4 and piperidine. m.p.: 101- 102 °C; 
1
H NMR 
(300 MHz, CDCl
3
): δ 1.26- 1.32 (m, 2H), 1.40-1.68 (m, 8H), 1.76-1.82 (m, 2H), 2.30-2.35 (m, 
6H), 4.05 (t, 2H), 6.34 (d, 1H), 6.42 (d, 1H), 7.32-7.37 (m, 1H), 7.44 (d, 1H), 7.71 (ddd, 1H), 
8.26 (dd, 1H), 12.82 (s, 1H, OH). 
13
C NMR (75 MHz, CDCl
3
): δ 24.2, 24.6, 26.1, 26.8, 29.0, 
54.8, 59.5, 68.7, 93.4, 97.6, 103.9, 117.8, 120.8, 124.1, 126.1, 134.9, 156.1, 157.9, 163.6, 166.4, 
180.9. IR (film):  3430, 2930, 2853, 1661, 1607, 1568, 1468, 1298, 1175, 1078, 823, 745 cm 
-1
. 
HRMS (EI) m/z: 381.1940 calcd for C
23
H
27
NO
4
, found 381.1945. 
 
1-hydroxy-3-((5-morpholinopentyl)oxy)-9H-xanthen-9-one (12) 
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Isolated yield: 82% (yellow solid) from compound 4 and morpholine. m.p.: 130-131 °C; 
1
H 
NMR (300 MHz, CDCl
3
): δ 1.35-1.50 (m, 4H), 1.62-1.75 (m, 2H), 2.41-2.55 (m, 6H), 4.04-4.11 
(m, 6H), 6.34 (d, 1H), 6.43 (d, 1H), 7.36-7.40 (m, 1H), 7.43 (d, 1H), 7.71 (ddd, 1H), 8.26 (dd, 
1H), 12.82 (s, 1H, OH).  
13
C NMR (75 MHz, CDCl
3
): δ 24.0, 26.3, 28.9, 46.5, 59.3, 68.2, 68.6, 
93.7, 97.4, 103.7, 117.6, 120.7, 124.1, 126.1, 135.1, 156.1, 157.9, 163.6, 166.3, 180.9. IR (film): 
 3432, 2941, 1654, 1609, 1568, 1466, 1319, 1266, 1168, 825, 744 cm
-1
. HRMS (EI) m/z: 
383.1733 calcd for C
22
H
25
NO
5
, found 383.1738. 
 
4.3. Biological activity 
4.3.1. Cholinesterase inhibition assay 
Electric eel AChE was used as source of cholinesterase. AChE inhibitory activity was measured 
in vitro by the spectrophotometric method developed by Ellman with slight modifications.
23
 The 
lyophilized enzyme (500 U) was dissolved in buffer phosphate A (8 mM K
2
HPO
4
, 2.3 mM 
NaH
2
PO
4
) to obtain 5 U/mL stock solution. Further enzyme dilution was carried out with buffer 
phosphate B (8 mM K
2
HPO
4
, 2.3 mM NaH
2
PO
4
, 0.15 M NaCl, 0.05% Tween 20, pH 7.6) to 
produce 0.126 U/mL enzyme solution. Samples were dissolved in buffer phosphate B with 2.5% 
of MeOH as cosolvent. Enzyme solution (300 μL) and sample solution (300 μL) were mixed in a 
test tube and incubated for 60 min at room temperature. The reaction was started by adding 600 
μL of the substrate solution (0.5 mM DTNB, 0.6 mM ATCI, 0.1 M Na
2
HPO
4
, pH 7.5). The 
absorbance was read at 405 nm for 120 s at 27 °C. Enzyme activity was calculated by comparing 
reaction rates for the samples to the blank. All reactions were performed in triplicate. IC
50
 values 
were determined with GraphPad Prism 5. Tacrine (99%) was used as the reference AChE 
inhibitor. 
 
 
 
4.4. Molecular modeling 
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The three-dimensional structures of the different molecules under evaluation were generated by 
means of the program UCSF- Chimera.
29
 
Molecular docking simulations of AChE from Torpedo californica (PDB: 1UT6) were performed 
with the Autodock 4 simulation package. The receptor structure was prepared by removing the 
organic molecule from the binding site together with crystallization water. The resulting structure 
was minimized, then Gasteiger charges were added and, finally, nonpolar hydrogen atoms were 
removed with the AutodockTools (ADT) program.
30
 The simulation box was defined so as to 
include all the residues of the catalytic site, bottlenecks and the peripheral anionic site of the 
enzyme. This procedure generated a grill of 86 points in each of the axis (X, Y, Z) with a 
separation of 0.375 Å between consecutive points.  
The analysis of interactions of the different complexes, as well as the 2D image, were made with 
LigPlot+ program.
31,32
 
For the molecular dynamics (MD) simulations we employed the AMBER 12 simulation package 
33
 with the ff99SB force field. In all cases the complexes were placed within cubic boxes with 
periodic boundary conditions. The different systems were then solvated with explicit water by 
using the TIP3P model. Production runs for all studied complexes were performed under the 
NPT ensemble at a temperature of 300 K. The length of such trajectories was 10 ns, recording a 
total amount of 2000 configurations in each case. In turn, in order to perform the MD 
simulations, we had to produce the topologies for the different organic. Thus, the parametrization 
of the different ligands was carried out with antechamber. 
34,35
 Finally, the post MD analysis was 
made with the CPPTRAJ program.
36
  
On the other hand, a solvation thermodynamic mapping study of the molecular Surface of AchE 
was conducted with GIST, recently included in AmberTools. We used the structure of AChE 
from Protein Data Bank (PDB: 1UT6). We removed the ligand from the binding site and used 
Tleap and other Amber Tools to assign protein parameters from the AMBER99SB force field 
and solvate the protein with TIP3P water molecules.  The simulations used a periodic box (with 
at least 10 Å between any protein atom and the edge of the periodic box). Three disulfide bonds 
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were set up to join cysteine pairs 67/94, 254/265, 402/521. Energy minimization, followed by 
MD simulation, was carried out with the Amber 12 software. First, the energy of the system was 
minimized in two rounds (both used 1500 steps of the steepest descents algorithm followed by 
the conjugate gradient method for a maximum of 2000 steps). In the first round, all protein atoms 
were harmonically restrained to their initial positions with a force constant of 100 kcal/mol/Å2. 
In the second round, the system was further relaxed keeping only non-hydrogen protein atoms 
restrained, with the same force constant. The energy-minimized system was then heated with a 
series of 20 ps constant-volume and constant-temperature MD simulations with the first 
simulation at 50 K and the temperature incremented by 50 K every 20 ps until 300 K was 
reached. The system was then equilibrated for 10 ns at 300 K at a constant pressure of 1 atm. At 
the final volume, the system was then equilibrated for an additional 5 ns at constant volume. The 
final MD production run of 120 ns was performed at constant number of particles, volume, and 
temperature (NVT), and system configurations were stored every 1 ps, for a total of 120 000 
stored configurations. Throughout each of the MD simulations, all protein atoms were 
harmonically restrained to their positions following the energy minimization step, with a force 
constant of 100 kcal/mol/Å. The SHAKE algorithm was used to constrain the lengths of all 
bonds involving hydrogen atoms. Temperature was regulated by Langevin dynamics with a 
collision frequency of 2.0 ps
−1
. A 9 Å cutoff was applied to all nonbonded interactions. Then, the 
main GIST solvation maps were produced from these configurations. 
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Highlights 
 
 New inhibitors of AChE based on the privileged xanthone scaffold are proposed. 
 A rational design of these target structures was conducted. 
 A new series of 1,3-dihydroxyxanthone derivatives were easily synthesized. 
 The results showed that most of the xanthone derivatives exhibited high AChE. 
 Amphiphilic xanthone 11 showed the best inhibitory effect (IC50: 0.46 M).  
 
